Aristo launches Probi's probiotics in India

Aristo launches Probi's probiotics in India

Probi's partner Institut Rosell has signed an agreement with the pharmaceutical
company Aristo Pharmaceuticals Ltd. to launch a dietary supplement based on
Probi's probiotics Lp 299v on the Indian market. Launch is planned for the fall
of 2007. With this agreement, Probi's probiotics are being launched in the
world's three most populated countries.

Aristo Pharmaceuticals Ltd. is a dynamic and rapidly growing pharmaceutical
company that is aiming for a position among the top five pharmaceutical
companies in India. 

“We are proud to expand the list of strategically important distributors with
Aristo Pharmaceuticals”, says Per-Ola Forsberg, executive vice president of
Probi. “High quality products, marketed by high quality distributors, will help
to develop Probi´s share of the market substantially. With the new agreement,
our probiotics will be launched in the world's three most populated countries:
India, China and the US.” 

Including the agreement with Aristo Pharmaceuticals, marketing of dietary
supplements containing Probi's probiotics is under way in fifteen countries. The
majority of the agreements have been signed within the past twelve months.
Considering the great interest shown by customers, prospects are good that the
business area Dietary Supplements will, within a two-year period, reach the same
sales level as shown by the business area Functional Food today.

French-Canadian Institut Rosell is one of the leading suppliers of probiotic
dietary supplements in the US and Europe. Probi and Institut Rosell are working
the market in parallel in order to reach the most effective market penetration
of Probi's bacteria Lp299v within dietary supplements. 


For further information please contact:
Per-Ola Forsberg, executive vice president of Probi, ph: +46-46-286 89 26 or
mobile +46-733-44 83 84 
e-mail: per-ola.forsberg@probi.se 
Rolf Bjerndell, acting president of Probi, ph: +46-46-286 89 23 or mobile
+46-705-15 30 09 
e-mail: rolf.bjerndell@probi.se
Olivier Clech, President, Institut Rosell, ph: +33 562 74 55 55
e-mail: oclech@lallemand.com


About Probi
Probi was founded in 1991 and is now one of the world's leading companies in the
field of probiotic R&D. The company's research focuses on live microorganisms
with scientifically demonstrated health-promoting effects. The main R&D fields
are gastrointestinal disorders, the immune system, cardiovascular diseases, and
stress and performance recovery. Probi's business is based on offering effective
and thoroughly documented probiotic products and concepts, protected by
comprehensive patents. This yields higher revenue levels than for the industry
as a whole. Probi has enjoyed a consistent income stream from commercialised
products since the mid-1990s. The customers comprise leading international
companies in the fields of functional food, dietary supplements and clinical
nutrition. 
The global market for probiotic products is showing good underlying growth while
new insights into the benefits offered by probiotics are boosting the market
still further. Increased documentation requirements and official regulation are
two trends that tend to give Probi an edge on its competitors. Probi is based in
Lund and has 17 employees. The Probi share is quoted on the Nordic Stock
Exchange. Fore more information, please visit www.probi.com.

About Aristo

Aristo Pharmaceuticals Private Limited was incorporated in the year 1971.Aristo
is now ranked twelfth (as per ORG-IMS, a globally renowned Market research firm)
amongst 25,000 pharmaceutical companies in India. Aristo's turnover during the
year 2005-2006 was Rs. 5.62 Billions (USD 125 million). Aristo has three large
state-of-the-art factories in India. The products are approved by WHO-GMP
Certification and SGS Belgium Certification. Aristo has about 3,000 employees.

Aristo is keen to establish strategic alliances for marketing innovative
products and to in-license research for new molecules for the Indian market.  A
partnership with Aristo gives instant access to well-knit marketing team of
1,700 professionals, distribution reach of over 2,500 stock-points and 75,000
chemists, and above all the goodwill of 150,000 members of the Indian medical
fraternity.

Aristo is uniquely positioned to manage the diversity of the Indian market since
Aristo enjoys:  
• Leadership positions in the mass markets (Antibiotics, NSAIDs, Nutritional
Supplements, Gastrointestinals) 
• Fast growth in speciality segments (Cardiovasculars, Antidiabetics,
Gynaecologicals)
• Dominant position in the rural markets 
• Emerging leadership in urban markets

Aristo exports and imports pharmaceutical products to and from many countries. 
Aristo presently has business agreements with few companies in European and
other countries. Aristo can be a guiding light to navigate through the complex
but vast fast growing and attractive Indian market.

About Rosell
Institut Rosell is a French Canadian Company specializing in the selection,
development, production and marketing of probiotic formulations for human
nutrition and health. Expert in live microorganisms since 1934, Institut Rosell
undertakes ambitious research programs so as to better understand the
properties, modes of action and beneficial effects on health of these probiotic
formulations. 
Institut Rosell is part of the Lallemand group, a privately owned company with
head offices in Montreal, Canada, and Toulouse, France, and production
facilities in various countries around the world. For more information, please
visit www.institut-rosell.com or contact human@lallemand.com